Unravelling Cancer Mechanism and Developing Novel Therapeutics: An Urgent Need to Treat Cancer (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 750

Special Issue Editors


E-Mail Website
Guest Editor
Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA
Interests: cancer; drug resistance; natural compound; targeted therapy; drug delivery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Microbiology, Immunology and Biochemistry, Morehouse School of Medicine, Atlanta, GA 30310, USA
2. Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA
Interests: targeted therapy; nano-therapy; nano-delivery; chemokine; combination therapy; prostate cancer; pancreatic cancer; liver cancer; ovarian cancer; breast cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent decades, concerns regarding cancer have grown rapidly. Many cancer screening programs are being implemented in high-and middle-income countries to reduce the incidence and mortality of cancer. However, the yearly rise in cases is disappointing considering the extensive use of various therapeutic approaches. Emerging evidence suggests that drug resistance and relapse also represent significant issues during treatment. Therefore, no single breakthrough can cure cancer; however, accumulating knowledge regarding the complex mechanisms implicated in the pathogenesis of cancer could reduce the associated mortality rate. Thus, understanding signaling pathways and developing novel targeted techniques, including molecular, biochemical, immunological, and nanotherapy, may provide clinicians searching for new targets for treatment with hope.

To address these challenges, this Special Issue aims to present novel targeted therapies and their underlying mechanism. The scope of this Special Issue therefore includes, but is not limited to, the following topics: natural compound combination therapy, chemotherapy, immunotherapy, and nanotherapy. We welcome you to submit original research and review articles that address recent advances in this field.

Dr. Rajesh Singh
Dr. Santosh Kumar Singh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • anticancer therapy
  • combination therapy
  • natural compound
  • nanotherapy
  • exosome therapy
  • targeted therapy
  • immunotherapy
  • chemokines
  • cytokines
  • antibodies
  • drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

28 pages, 1534 KiB  
Review
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy
by Whi-An Kwon and Jae Young Joung
Cancers 2025, 17(11), 1820; https://doi.org/10.3390/cancers17111820 - 29 May 2025
Viewed by 522
Abstract
Advanced prostate cancer (PCa) remains lethal despite standard therapies, and immune checkpoint inhibitors offer limited benefit in its “immune-cold” microenvironment. T-cell engagers (TCEs)—bispecific antibodies linking CD3 on T-cells to tumor-associated antigens (TAAs)—provide potent, MHC-independent cytotoxicity, overcoming a key resistance mechanism. While early PSMA-targeted [...] Read more.
Advanced prostate cancer (PCa) remains lethal despite standard therapies, and immune checkpoint inhibitors offer limited benefit in its “immune-cold” microenvironment. T-cell engagers (TCEs)—bispecific antibodies linking CD3 on T-cells to tumor-associated antigens (TAAs)—provide potent, MHC-independent cytotoxicity, overcoming a key resistance mechanism. While early PSMA-targeted TCEs established proof-of-concept, recent data, notably for six transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeting agents like Xaluritamig, demonstrate more substantial objective responses, highlighting progress through improved target selection and molecular design. This review synthesizes the evolving landscape of TCEs targeting PSMA, STEAP1, and DLL3 in PCa. We critically evaluate emerging clinical evidence, arguing that realizing the significant therapeutic potential of TCEs requires overcoming key challenges, including cytokine release syndrome (CRS), limited response durability, and antigen escape. We contend that future success hinges on sophisticated engineering strategies (e.g., affinity tuning, masking, multispecific constructs) and rationally designed combination therapies tailored to disease-specific hurdles. Strategies for toxicity mitigation, the crucial role of biomarker-driven patient selection, and potential integration with existing treatments are also discussed. Accumulating evidence supports TCEs becoming a new therapeutic pillar for advanced PCa, but achieving this demands sustained innovation focused on optimizing efficacy and safety. This review critically connects molecular engineering advancements with clinical realities and future imperatives. Full article
Show Figures

Figure 1

Back to TopTop